Videos

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.

Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.

Helen Thackray, MD, provides a brief overview and highlights of the RESET clinical trial.

In an interview with Pharmacy Times, Stefan Behrens, PhD, CEO and co-founder of GYANT, and Justin Graham, MD, MS, chief medical officer, said preparing patients for the process of receiving a coronavirus disease 2019 (COVID-19) vaccine is essential.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on his closing thoughts on the research he conducted into the induction of fetal hemoglobin by FTX6058.

Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on 3 new patient cases from their presentation and the significance of these cases to their research.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on the results observed in his research when treating donors who were healthy or had sickle cell disease with FTX-6058.

Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on the process for the diagnosis of patients with congenital plasminogen deficiency.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what their parallel target identification efforts were able to identify, and how this identification was important in his research.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the implications of the results of his research on further investigation and treatment opportunities for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the noteworthy results observed in the study in relation to cause of death among patients with polycythemia vera.